

Day 1 (Friday, April 23, 2010)

Opening

9:30 – 9:40	Welcome & Introduction	Takashi Sugimura, National Cancer Center
9:40 – 9:50	Opening Address	Yasuhiro Fujiwara, National Cancer Center

<Drug development>

Session 1: HER2-positive breast cancer

Chairperson: Seigo Nakamura, St. Luke's International Hospital

9:50 – 10:10		Takayuki Ueno, Kyoto Univ.
10:10 – 10:35		Norah Lynn Henry, Univ. of Michigan
10:35 – 10:40	Q&A	
10:40 – 11:00	Coffee Break	

Session 2: Triple-negative breast cancer

Chairperson: Hirotaka Iwase, Kumamoto Univ.

11:00 – 11:20		Tomohiko Ohta, St. Marianna Univ.
11:20 – 11:45		Virginia G Kaklamani, Northwestern Univ.
11:45 – 11:50	Q&A	
11:50 – 13:10	Lunch	

Session 3: Hormone-receptor positive breast cancer

Chairperson: Junichi Kurebayashi, Kawasaki Medical School

13:10 – 13:30		Shinichi Hayashi, Tohoku Univ.
13:30 – 13:55		Gunter von Minckwitz, German Breast Group, Neu-Isenburg/Frankfurt
13:55 – 14:00	Q&A	

Discussion of drug development

14:00 – 14:30		Lisa Carey, Univ. of North Carolina
14:30 – 14:40	Q&A	
14:40 – 15:00	Coffee Break	

<Emerging technologies towards tailored-treatment>

Chairpersons: Shinzaburo Noguchi, Osaka University
Kenji Tamura, National Cancer Center Hospital

Session 4: Prediction using genetic technologies

15:00 – 15:20		Yasuto Naoi, Osaka Univ.
15:20 – 15:45		W. Fraser Symmans, M.D. Anderson Cancer Center
15:45 – 15:50	Q&A	
15:50 – 16:10		Hideyuki Saya, Keio Univ.

Session 5: Innovative clinical trial design in the early clinical development

Chairperson: Seiichiro Yamamoto, National Cancer Center

16:10 – 16:40		Donald A. Berry, M.D. Anderson Cancer Center
16:40 – 16:50	Q&A for Session 4 & 5	

Day 2 (Saturday, April 24, 2010)

<Critical appraisal of new drugs and technologies>

Session 6: Pitfalls in the development and validation of prognostic and predictive biomarkers

Chairperson: Yasutsuna Sasaki, Saitama Medical School

9:00 – 9:20	Hironobu Minami, Kobe Univ.
9:20 – 9:45	Lyndsay Harris, Yale Univ.
9:45 – 10:10	Bostjan Seruga, Princess Margaret Hospital
10:10 – 10:35	Christof von Kalle, National Center for Tumor Diseases Heidelberg
10:35– 10:40	Q&A

Session 7: Cost-effectiveness and outcome researches of new targeted drugs and prognostic/predictive tools

Chairperson: Masakazu Toi, Kyoto Univ.

10:40 – 11:00	Masahide Kondo, Tsukuba Univ.
11:00 – 11:25	Michael Hassett, Dana-Farber Cancer Institute
11:25 – 11:50	Martin Stockler, Univ. of Sydney
11:50 – 11:55	Q&A

Discussion of Emerging technologies towards tailored-treatment and Critical appraisal of new drugs and technologies

11:55 – 12:40	Robert Bast, M.D. Anderson Cancer Center
12:40 – 13:10	Q&A
13:10 – 14:30	Lunch

<Introduction of new drugs and technologies in healthcare systems>

Session 8: Introduction of new drugs and technologies in healthcare systems

Chairpersons: Yasuhiro Fujiwara, National Cancer Center Hospital
Chikako Shimizu, National Cancer Center Hospital

14:30 – 14:55	Patricia Goldsmith, National Comprehensive Cancer Network (NCCN)
14:55 – 15:20	Sarah Garner, National Institute for Health and Clinical Excellence (NICE UK)
15:20 – 15:25	Q&A
15:25 – 15:40	Coffee Break
15:40 – 16:00	Masako Ii, Hitotsubashi Univ.
16:00 – 16:25	John Smyth, Univ. of Edinburgh
16:25 – 16:55	Ronald Walters, M.D. Anderson Cancer Center
16:55 – 17:00	Q&A

Discussion of Introduction of new drugs and technologies in healthcare systems

17:00 – 17:30	John Smyth, Univ. of Edinburgh
17:30 – 17:40	Q&A

Day 3 (Sunday, April 25, 2010)

<Patients' perspectives on drug development, personalized treatment and healthcare cost>

Session 9: Patient Advocacy

Chairperson: Thomas Jordan, Tom Jordan Consulting

9:00 – 9:30		Naomi Sakurai, HOPE Project
9:30 – 10:00		Mary Lou Smith, Research Advocacy Network
10:00 – 10:30		Ingrid Kossler, Swedish Breast Cancer Association
10:30 – 10:50	Discussion / Q&A	
10:50 – 11:10	Coffee Break	

Wrap-up Discussion and Closing Remarks

11:10 – 11:40		Richard Theriault, M.D. Anderson Cancer Center
11:40 – 11:50		Yasuhiro Fujiawara, National Cancer Center Hospital
11:50 – 13:10	Lunch	